# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Chronic Myelomonocytic Leukemia

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 78 results.
Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)
Status: Recruiting
Last Changed: Mar 19, 2018
First Received: Sep 13, 2017
Disease(s): Chronic Myelomonocytic Leukemia
Locations: CHU de Nice, Nice, France
The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
Status: Recruiting
Last Changed: Feb 21, 2019
First Received: Nov 09, 2009
Disease(s): Chronic Myelomonocytic Leukemia
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Status: Recruiting
Last Changed: Jul 04, 2019
First Received: Oct 29, 2018
Disease(s): Chronic Myelomonocytic Leukemia, Leukemia
Intervention(s): Ruxolitinib
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia
Status: Recruiting
Last Changed: Oct 12, 2017
First Received: Jun 21, 2016
Disease(s): Leukemia, Myelomonocytic, Chronic
Intervention(s): Tipifarnib
Locations: UC San Diego Moores Cancer Center, La Jolla, California, United States
H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, Florida, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Mayo Clinic, Rochester, Minnesota, United States
Weill Cornell Medicine, New York, New York, United States
... and 3 other locations.
A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)
Status: Recruiting
Last Changed: Dec 19, 2017
First Received: Feb 02, 2017
Disease(s): Leukemia, Myelomonocytic, Chronic
Intervention(s): Cohort 1, Ceplene® and Proleukin®, Cohort 2, Ceplene® and Proleukin®, Cohort 3, Ceplene® and Proleukin®
Locations: Sahlgrenska University Hospital, Gothenburg, Sweden
Karolinska University Hospital, Huddinge, Stockholm, Sweden
SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Primary Eosinophilic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)
Status: Recruiting
Last Changed: Mar 01, 2019
First Received: Oct 20, 2014
Disease(s): Myelofibrosis, Chronic Myelomonocytic Leukemia
Intervention(s): SL-401
Locations: City of Hope, Duarte, California, United States
University of California, Los Angeles, Los Angeles, California, United States
University of Kansas Cancer Center, Westwood, Kansas, United States
University of Michigan, Ann Arbor, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
... and 6 other locations.
A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Status: Recruiting
Last Changed: Feb 22, 2019
First Received: Jul 22, 2016
Disease(s): Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Intervention(s): H3B-8800
Locations: Stanford Cancer Center, Stanford, California, United States
SCRI - Colorado Blood Cancer Institute, Denver, Colorado, United States
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
University of Miami, Miami, Florida, United States
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
... and 23 other locations.
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
Status: Recruiting
Last Changed: Jul 08, 2019
First Received: Oct 17, 2016
Disease(s): Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Intervention(s): Atezolizumab, Guadecitabine
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of Maryland Medical Center, Baltimore, Maryland, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Temple University Hospital, Philadelphia, Pennsylvania, United States
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Recruiting
Last Changed: Aug 13, 2019
First Received: Aug 31, 2017
Disease(s): Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Intervention(s): Azacitidine, Pevonedistat
Locations: Southern Cancer Center, Daphne, Alabama, United States
Southern Cancer Center, Mobile, Alabama, United States
Southern Cancer Center, Mobile, Alabama, United States
Cancer Treatment Centers of America, Goodyear, Arizona, United States
Arizona Oncology Associates (Orange HOPE) - USOR, Tucson, Arizona, United States
... and 236 other locations.
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
Status: Recruiting
Last Changed: Sep 24, 2018
First Received: Sep 14, 2005
Disease(s): Juvenile Myelomonocytic Leukemia
Intervention(s): Stem Cell Transplant, Preparative Regimen
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States